3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Virus Diseases
1
Tumor Virus Infections
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Head and Neck Neoplasms
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
Cisplatin
55
Radiotherapy
33
Cetuximab
25
Paclitaxel
23
Carboplatin
23
Radiotherapy, Intensity-Modulated
21
pembrolizumab
19
Docetaxel
17
Fluorouracil
16
Nivolumab
14
Drug Therapy
11
Radiation
9
Erlotinib Hydrochloride
8
Blood Specimen Collection
8
durvalumab
7
Magnetic Resonance Spectroscopy
7
Surveys and Questionnaires
6
atezolizumab
5
Surgical Procedures, Operative
5
Radiosurgery
5
Esophagectomy
5
Chemoradiotherapy
5
olaparib
4
dacomitinib
4
Leucovorin
4
Cyclophosphamide
4
Capecitabine
4
Biopsy
4
Afatinib
4
fludarabine phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Squamous Cell
×
Nimorazole
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled